Created at	Source	Raw Value	Validated value
Nov. 15, 2021, 6:30 p.m.	usa	Evaluate the ability of INNA-051 to reduce the incidence of symptomatic RT-PCR confirmed SARS-CoV-2 infection;Evaluate the safety and tolerability of INNA 051.	Evaluate the ability of INNA-051 to reduce the incidence of symptomatic RT-PCR confirmed SARS-CoV-2 infection;Evaluate the safety and tolerability of INNA 051.